A Christmas Message to the DEA’s Diversion Anti Marijuana Cabal 
The Ensign Group, Inc. Declares Quarterly Dividend of $0.0525 Per Share
SAN JUAN CAPISTRANO, Calif., March 19, 2021 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (NASDAQ: ENSG), the parent company of...
Angion Announces Partial Waiver of Certain Lock-up Restrictions
UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery,...
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19,...
Finch Therapeutics Announces Pricing of Upsized Initial Public Offering
SOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...
Connect Biopharma Holdings Limited announces pricing of Initial Public Offering
SAN DIEGO and TAICANG, China, March 18, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (the “Company”), a global clinical-stage...
Solid Biosciences Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing...
Instil Bio Announces Pricing of Upsized Initial Public Offering
DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative...
REPLACING: Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 Results
Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1%RARITAN, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- In a release...
Cyclerion Therapeutics Announces Departure of Chief Medical Officer
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission...
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
-- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan...
Kane Biotech to Release Fourth Quarter and Full Year 2020 Financial Results on March 25 – Conference Call to Follow
WINNIPEG, Manitoba, March 18, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a...
Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results
AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
Precipio Announces Q4-2020 and year-end Shareholder Update Call
Conference Call to be held on Wednesday, March 31st, 2021 at 5:00 PM ESTNEW HAVEN, Conn., March 18, 2021 (GLOBE...
Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
- ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis -- Commercial launch expected in April 2021 -- Kiniksa...
IntelGenx to Report Fourth Quarter and Full-Year 2020 Financial Results on March 25, 2021 – Conference Call to Follow
SAINT LAURENT, Quebec, March 18, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will...
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
– Objective Response Rate Endpoint Not Met –EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA;...
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Topline data from Phase 2b clinical trial evaluating rNAPc2...
ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
BURLINGAME, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company...
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional...